Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Nagaraja

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Rheumatology (Oxford, England)|November 15, 2022
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohortAhmad Ramahi, Alain Lescoat, David Roofeh, et al.
Arthritis Research & Therapy|September 5, 2019
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcersVivek Nagaraja, Cathie Spino, Erica Bush, et al.
Clinical and Experimental Rheumatology|September 10, 2019
Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung diseaseCaitlyn J Fisher, Rajaie Namas, Daniela Seelman, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A pilot trial of integrating the Patient-Reported Outcome Measurement Information System (PROMIS®) into rheumatology careRosemary Gedert, Danielle Ochocki, Neda Kortam, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 7, 2017
Establishing clinical severity for PROMIS<sup>®</sup> measures in adult patients with rheumatic diseasesVivek Nagaraja, Constance Mara, Puja P Khanna, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
JCI Insight|August 9, 2022
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trialDinesh Khanna, Cristina Padilla, Lam C Tsoi, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Review of abdominal damage control and open abdomens: focus on gastrointestinal complicationsBrian P Smith, Raeanna C Adams, Vijay A Doraiswamy, et al.
ACR Open Rheumatology|December 3, 2022
Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional StudyJulia K Weiner, Tristin Smith, Claire K Hoy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Rheumatology (Oxford, England)|November 15, 2022
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohortAhmad Ramahi, Alain Lescoat, David Roofeh, et al.
Arthritis Research & Therapy|September 5, 2019
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcersVivek Nagaraja, Cathie Spino, Erica Bush, et al.
Clinical and Experimental Rheumatology|September 10, 2019
Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung diseaseCaitlyn J Fisher, Rajaie Namas, Daniela Seelman, et al.
Clinical and Experimental Rheumatology|October 31, 2024
A pilot trial of integrating the Patient-Reported Outcome Measurement Information System (PROMIS®) into rheumatology careRosemary Gedert, Danielle Ochocki, Neda Kortam, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 7, 2017
Establishing clinical severity for PROMIS<sup>®</sup> measures in adult patients with rheumatic diseasesVivek Nagaraja, Constance Mara, Puja P Khanna, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
JCI Insight|August 9, 2022
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trialDinesh Khanna, Cristina Padilla, Lam C Tsoi, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Review of abdominal damage control and open abdomens: focus on gastrointestinal complicationsBrian P Smith, Raeanna C Adams, Vijay A Doraiswamy, et al.
ACR Open Rheumatology|December 3, 2022
Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional StudyJulia K Weiner, Tristin Smith, Claire K Hoy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
Pageof 4